fin rev article, page-16

none taken kates. gd to see u on here and appreciate ur ta on this amongst others.

like you mentioned, you really have to be holding shares before ann are out. a licensing agreement will easily double the sp within a day for micro-cap pharma coy.

from e exchange of emails as well as previous ann from coy, i do expect more license agreements with big names by years end and Dr Cummings doesnt rule out one before the AGM.

southern cross equities recommends a spec buy in their report; valuing Anteo at $0.13 per share base case and $0.24 optimistic case using a high-discount-rate (ie 25%) DCF valuation. their target price of $0.13 sits at their base case valuation. they see potential for a rerating of Anteo as further licensing deals emerge and early revenue is generated from Bangs and Merck.